Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1CNS 1Breast 1

Conditions

Breast Neoplasms 300Carcinoma, Non-Small-Cell Lung 225Neoplasms 195Prostatic Neoplasms 164Multiple Myeloma 139Neoplasm Metastasis 117Melanoma 113Colorectal Neoplasms 108Leukemia, Myeloid, Acute 107Lung Neoplasms 98Lymphoma 97Ovarian Neoplasms 87Squamous Cell Carcinoma of Head and Neck 77Lymphoma, Non-Hodgkin 73Leukemia, Lymphocytic, Chronic, B-Cell 72Myelodysplastic Syndromes 65Triple Negative Breast Neoplasms 64Pancreatic Neoplasms 64Hematologic Neoplasms 60Parkinson Disease 4, Autosomal Dominant Lewy Body 59Head and Neck Neoplasms 59Glioblastoma 58Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Recurrence 56Leukemia 56Sarcoma 50Brain Neoplasms 50Lymphoma, Large B-Cell, Diffuse 48Carcinoma, Hepatocellular 47Lymphoma, Follicular 46

Interventions

tucatinib 1sapanisertib 1Trastuzumab 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Meningeal Neoplasms × 1 year × Clear all
NCT04250545 2026-05-26

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
22 enrolled 14 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Neoplasms

NCT03501979 2025-08-29

Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

University of Alabama at Birmingham

Phase 2 Terminated
17 enrolled 16 charts
Breast

Breast Neoplasms, Meningeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡